MIRA
INFORM REPORT
|
Report Date : |
16.03.2007 |
IDENTIFICATION
DETAILS
|
Name : |
HEBI PHARMACEUTICALS RAW MATERIALS |
|
|
|
|
Registered Office : |
3rd
Industrial Zone, Keft City, Qena |
|
|
|
|
Country : |
Egypt |
|
|
|
|
Date of Incorporation : |
1998 |
|
|
|
|
Com. Reg. No.: |
47821 |
|
|
|
|
Legal Form : |
Egyptian Joint Stock Company |
|
|
|
|
Line of Business : |
Engaged
in the manufacture and export of pharmaceutical specialities and raw
materials for medical use. |
RATING &
COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
US$ 500,000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
SUMMARY
Company Name : HEBI PHARMACEUTICALS RAW MATERIALS
Country of Origin : Egypt
Legal Form : Egyptian Joint Stock Company
Registration Date : 1998
Commercial Registration Number : 47821
Authorised Capital : £E 40,000,000
Issued Capital : £E 20,000,000
Paid up Capital : £E 20,000,000
Total Workforce : 400
Line of Business :
Manufacture and export of pharmaceutical
specialities and raw materials for medical use.
Financial Condition : Undetermined
Payments : Nothing detrimental uncovered
COMPANY NAME
HEBI PHARMACEUTICALS RAW MATERIALS
ADDRESS
Registered & Physical Address
Location : 3rd
Industrial Zone, Keft City
Town : Qena
Country : Egypt
Telephone : (20-96) 5420062
/ 5420064 / 5420059 / 5420057
Facsimile : (20-96) 5420053
Premises
Subject operates
from a large suite of offices and a factory that are owned and located in the
Industrial Area of Qena.
Branch Office (s)
Location Description
·
Nile
Tower, 16th Floor Rented
office premises
21/23
Charles De Gaulle Street
Giza
Cairo
Tel: (20-2)
5713424 / 5713425
Fax: (20-2)
5713440
KEY PRINCIPALS
·
Dr.
Refaat Mohamed El Sayed Chairman
·
Mohamed
Adel Ewies Director
·
Samir
Metlwally Director
·
Dr.
Moawad Hussien Director
·
Hamdy
Nada Director
·
Adnan
El Sharkawy Director
·
Mounir
Shafik Barssoum Director
·
Dr.
Salah El Din Ibrahim Shehata Director
·
Dr.
Ibrahim Fawzy Director
·
Moustafa
Kamel Mourad Director
·
Dr.
Maher Wally Director
·
Dr.
Ragab Abd El Aziz General
Manager
·
Dr.
Abd El Rahman Shabana Deputy
General Manager
·
Maher
Rashad Finance
Manager
·
Mahmoud
Zayed Marketing
Manager
LEGAL FORM &
OWNERS
Date of Establishment : 1998
Legal Form :
Societe Anonyme Egyptienne –
SAE (Egyptian Joint Stock Company)
Commercial Reg. No. : 47821
Authorised
Capital : £E 40,000,000
Issued Capital : £E 20,000,000
Paid up Capital : £E 20,000,000
Name of Shareholder
(s) Percentage
·
Hebi
Health Care 47.00%
Sweden
·
Hebi
Holding 26.00%
Sweden
·
Suez
Canal Bank 10.00%
·
Mohandes
Insurance 5.00%
·
National
Bank of Egypt 3.75%
·
Egyptian
Abroad 1.88%
·
Integrated
Egyptian Industries 1.68%
·
Dr.
Salah El Din Ibrahim Shehata 3.75%
·
Dr.
Mohsen Mohamed Shalaby 0.94%
Note to the Legal Form
The Egyptian Company Law provides that the capital of a Societe
Anonyme Egyptienne - SAE – should not be less than £E 500,000 if shares are
offered to the public and £E 250,000 if not. If shares are offered to the
public they are freely transferable, if not, transfer may be restricted.
Liability of shareholders is limited.
LINE OF BUSINESS
Operations : Engaged in the
manufacture and export of pharmaceutical specialities and raw materials for
medical use.
Import Countries
: India and Europe.
Export Countries
: Spain and China.
Subject has a
workforce of approximately 400 employees.
FINANCIAL HIGHLIGHTS
Companies registered
in Egypt are not legally required to make their accounts public and no
financial information was released by the company or submitted by outside
sources.
BANKERS
·
Commercial
International Bank (CIB)
Nile Tower Building
21-23 Giza Street
PO Box : 2430
Cairo
Tel : (20-2) 5703043
Fax : (20-2) 5703172 / 5072691
·
National Bank
of Egypt
24, Sherif Street
Cairo
Tel : (20-2) 3924175
Fax : (20-2) 3924143
PAYMENT HISTORY
No complaints
regarding subject’s payments have been reported.
GENERAL COMMENTS
During the course
of this investigation nothing detrimental was uncovered regarding subject’s
operating history or the manner in which payments are fulfilled. As such the
company is considered to be a fair trade risk.
Maximum suggested credit
figure: US$ 500,000
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)